Unknown PHASE4 INTERVENTIONAL 2-arm NCT01869309

Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor (HEIGHTEN)

Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy

Sponsor: AstraZeneca

Updated 5 times since 2017 Last updated: Nov 20, 2014 Started: Jan 31, 2014 Primary completion: Dec 31, 2015 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Coronary Artery Disease and is currently ongoing. AstraZeneca leads this study, which shows 5 recorded versions since 2014 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
LifeBridge Health

Data source: LifeBridge Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States